Previous close | 1.5000 |
Open | 1.5000 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 1.5000 - 1.5000 |
52-week range | 1.0400 - 1.9500 |
Volume | |
Avg. volume | 46 |
Market cap | 53.776M |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.3400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Election of the board of directors and auditor
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").